InvestorsHub Logo
Followers 14
Posts 733
Boards Moderated 0
Alias Born 12/09/2013

Re: biotech_researcher post# 728

Thursday, 12/11/2014 12:53:28 AM

Thursday, December 11, 2014 12:53:28 AM

Post# of 2944
I hate to jinx it, but the tale of the tape has been good lately. I keep coming back to this chart;

http://finviz.com/quote.ashx?t=enta&ty=c&ta=1&p=d

Looks like a newer tighter ascending channel has formed.

I think the approval is a given
The next quarter should show increased earnings
The there is a list of catalysts which should continue to propel share price.
USA approval, EU approval (For 1 and 4 genotypes)
Approval in Japan 2016
2nd generation HCV program approval in 2017/18 time frame.

Daily volume is increasing, market cap keeps increasing....

I believe the 2nd generation program is going well, so the royalty stream should be good for some time to come.

Antibiotics in the news lately; ENTA may have a great under-appreciated asset.

We should hear more about the other ENTA assets early in 2015 according to CEO Jay Luly.

There is a lot of potential here, and the company is going to start getting a lot more press......

If you merely bought and held this year you did better with this stock than with Gilead. I believe that may repeat again this year.

We may see some turbulence when Abbvie prices the drug combo however.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News